COPD exacerbations are associated with proinfl ammatory degradation of hyaluronic acid

Chest

Volumn 148, Issue 6, 2015, Pages 1497-1507

  Papakonstantinou, Eleni ^a   Roth, Michael ^a   Klagas, Ioannis ^b   Karakiulakis, George ^b   Tamm, Michael ^a   Stolz, Daiana ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYALURONIC ACID; HYALURONIC ACID SYNTHASE 1; HYALURONIDASE; SYNTHETASE; UNCLASSIFIED DRUG; GLUCURONOSYLTRANSFERASE; HAS1 PROTEIN, HUMAN; HYALURONOGLUCOSAMINIDASE;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; EXTRACELLULAR MATRIX; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; LUNG ALVEOLUS MACROPHAGE; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NEUTROPHIL COUNT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY OF LIFE; SURVIVAL PREDICTION; ZYMOGRAPHY; AIRWAY OBSTRUCTION; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE COURSE; IMMUNOLOGY; INFLAMMATION; LUNG FUNCTION TEST; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ACUITY; PROCEDURES; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; STATISTICS;

ADULT; AGED; AIRWAY OBSTRUCTION; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; INFLAMMATION; MALE; MIDDLE AGED; PATIENT ACUITY; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; STATISTICS AS TOPIC;

EID: 84949032170     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0153     Document Type: Article

References (44)

1. Postma DS, Timens W. Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006; 3(5):434-439.
2. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jefries DJ, Wedzicha JA. effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 pt 1):1418-1422.
3. Papakonstantinou E, Karakiulakis G. The 'sweet' and 'bitter' involvement of glycos-aminoglycans in lung diseases: pharma-cotherapeutic relevance. Br J Pharmacol. 2009;157(7):1111-1127.
4. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol. 2006;85(8): 699-715.
5. Itano N, Sawai T, Yoshida M, et al. Three isoforms of mammalian hyaluronan syn-thases have distinct enzymatic properties. J Biol Chem. 1999;274(35):25085-25092.
6. Papakonstantinou E, Kouri FM, Karakiulakis G, Klagas I, Eickelberg O. Increased hyaluronic acid content in idio-pathic pulmonary arterial hypertension. Eur Respir J. 2008;32(6):1504-1512.
7. Klagas I, Goulet S, Karakiulakis G, et al. Decreased hyaluronan in airway smooth muscle cells from patients with asthma and COPD. Eur Respir J. 2009;34(3): 616-628.
8. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6): 532-555.
9. Dentener MA, Vernooy JH, Hendriks S, Wouters EF. Enhanced levels of hyal-uronan in lungs of patients with COPD: relationship with lung function and local infammation. Thorax. 2005;60(2): 114-119.
10. Stolz D, Chhajed PN, Leuppi JD, Brutsche M, Pfimlin E, Tamm M. Cough suppression during flexible bronchos-copy using combined sedation with mid-azolam and hydrocodone: a randomised, double blind, placebo controlled trial. Thorax. 2004;59(9):773-776.
11. Stolz D, Stulz A, Müller B, Gratwohl A, Tamm M. BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest. 2007;132(2):504-514.
12. Grendelmeier P, Tamm M, Pfimlin E, Stolz D. Propofol sedation for flexible bronchoscopy: a randomised, noninferi-ority trial. Eur Respir J. 2014;43(2): 591-601.
13. Schlatter L, Pfimlin E, Fehrke B, Meyer A, Tamm M, Stolz D. Propofol versus propofol plus hydrocodone for flexible bronchoscopy: a randomised study. Eur Respir J. 2011;38(3):529-537.
14. Bot PT, Pasterkamp G, Goumans MJ, et al. Hyaluronic acid metabolism is increased in unstable plaques. Eur J Clin Invest. 2010;40(9):818-827.
15. Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(4):356-361.
16. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672-688.
17. Toole BP. Glycosaminoglycans in morphogenesis. In: Hay ED, ed. Cell Biology of Extracellular Matrix. 2nd ed. New York, NY: Plenum Press; 1991:259-294.
18. Partsch G, Schwarzer C, Neumüller J, et al. Modulation of the migration and chemotaxis of PMN cells by hyaluronic acid. Z Rheumatol. 1989;48(3):123-128.
19. Cantor JO, Cerreta JM, Armand G, Osman M, Turino GM. The pulmonary matrix, glycosaminoglycans and pulmonary emphysema. Connect Tissue Res. 1999;40(2):97-104.
20. Noble PW, Jiang D. Matrix regulation of lung injury, inf ammation, and repair: the role of innate immunity. Proc Am Thorac Soc. 2006;3(5):401-404.
21. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol. 2007;23:435-461.
22. Noble PW, McKee CM, Cowman M, Shin HS. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha auto-regulatory loop in murine macrophages. J Exp Med. 1996;183(5):2373-2378.
23. Horton MR, Burdick MD, Strieter RM, Bao C, Noble PW. Regulation of hyaluronan-induced chemokine gene expression by IL-10 and IFN-gamma in mouse macrophages. J Immunol. 1998;160(6):3023-3030.
24. Li Y, Rahmanian M, Widström C, Lepperdinger G, Frost GI, Heldin P. Irradiation-induced expression of hyaluronan (HA) synthase 2 and hyaluronidase 2 genes in rat lung tissue accompanies active turnover of HA and induction of types I and III collagen gene expression. Am J Respir Cell Mol Biol. 2000; 23(3):411-418.
25. Casalino-Matsuda SM, Monzón ME, Forteza RM. Epidermal growth factor receptor activation by epidermal growth factor mediates oxidant-induced goblet cell metaplasia in human airway epithelium. Am J Respir Cell Mol Biol. 2006;34(5):581-591.
26. Šoltés L, Mendichi R, Kogan G, Schiller J, Stankovska M, Arnhold J. Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules. 2006; 7(3):659-668.
27. Gao F, Koenitzer JR, Tobolewski JM, et al. Extracellular superoxide dismutase inhibits inf ammation by preventing oxidative fragmentation of hyaluronan. J Biol Chem. 2008;283(10):6058-6066.
28. Monzon ME, Fregien N, Schmid N, et al. Reactive oxygen species and hyal-uronidase 2 regulate airway epithelial hyaluronan fragmentation. J Biol Chem. 2010;285(34):26126-26134.
29. Cheng G, Swaidani S, Sharma M, Lauer ME, Hascall VC, Aronica MA. Correlation of hyaluronan deposition with inf ltration of eosinophils and lymphocytes in a cockroach-induced murine model of asthma. Glycobiology. 2013;23(1):43-58.
30. Chang MY, Tanino Y, Vidova V, et al. A rapid increase in macrophage-derived versican and hyaluronan in infectious lung disease. Matrix Biol. 2014; 34: 1-12.
31. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 2011;91(1):221-264.
32. Horton MR, Olman MA, Bao C, et al. Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluro-nan fragments in mouse macrophages. Am J Physiol Lung Cell Mol Physiol. 2000;279(4):L707-L715.
33. Horton MR, Shapiro S, Bao C, Lowenstein CJ, Noble PW. Induction and regulation of macrophage metal-loelastase by hyaluronan fragments in mouse macrophages. J Immunol. 1999;162(7):4171-4176.
34. Sokolowska M, Chen LY, Eberlein M, et al. Low molecular weight hyaluronan activates cytosolic phospholipase A2 a and eicosanoid production in mono-cytes and macrophages. J Biol Chem. 2014;289(7):4470-4488.
35. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest. 1996;98(10):2403-2413.
36. Ohkawara Y, Tamura G, Iwasaki T, Tanaka A, Kikuchi T, Shirato K. Activation and transforming growth factor-beta production in eosinophils by hyaluronan. Am J Respir Cell Mol Biol. 2000;23(4):444-451.
37. Sutherland IW. Polysaccharide lyases. FEMS Microbiol Rev. 1995;16(4):323-347.
38. Matsushita O, Okabe A. Clostridial hydro-lytic enzymes degrading extracellular components. Toxicon. 2001;39(11):1769-1780.
39. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev. 2001;65(2):187-207.
40. Jedrzejas MJ. Extracellular virulence factors of Streptococcus pneumoniae. Front Biosci. 2004;9:891-914.
41. Makris G, Wright JD, Ingham E, Holland KT. The hyaluronate lyase of Staphylococcus aureus-a virulence factor? Microbiology. 2004;150(6): 2005-2013.
42. Cantor JO, Cerreta JM, Armand G, Keller S, Turino GM. Pulmonary air-space enlargement induced by intratracheal instillment of hyaluroni-dase and concomitant exposure to 60% oxygen. Exp Lung Res. 1993;19(2): 177-192.
43. Cantor JO, Shteyngart B, Cerreta JM, Liu M, Armand G, Turino GM. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc Soc Exp Biol Med. 2000;225(1):65-71.
44. Song WD, Zhang AC, Pang YY, et al. Fibronectin and hyaluronan in bron-choalveolar lavage fluid from young patients with chronic obstructive pulmonary diseases. Respiration. 1995;62(3): 125-129.